Literature DB >> 23333650

A success in Toxinology translational research in Brazil: bridging the gap.

Ana Silvia S B S Ferreira1, Benedito Barraviera, Silvia Regina C S Barraviera, Luciana P F Abbade, Carlos Antonio Caramori, Rui Seabra Ferreira.   

Abstract

Basic research is fundamental for discovering potential diagnostic and therapeutic tools, including drugs, vaccines and new diagnostic techniques. On this basis, diagnosis and treatment methods for many diseases have been developed. Presently, discovering new candidate molecules and testing them in animals are relatively easy tasks that require modest resources and responsibility. However, crossing the animal-to-human barrier is still a great challenge that most researchers tend to avoid. Thus, bridging this current gap between clinical and basic research must be encouraged and elucidated in training programmes for health professionals. This project clearly shows the challenges faced by a group of Brazilian researchers who, after discovering a new fibrin sealant through 20 years of painstaking basic work, insisted on having the product applied clinically. The Brazilian government has recently become aware of this challenge and has accordingly defined the product as strategic to the public health of the country. Thus, in addition to financing research and development laboratories, resources were invested in clinical trials and in the development of a virtual platform termed the Virtual System to Support Clinical Research (SAVPC); this platform imparts speed, reliability and visibility to advances in product development, fostering interactions among sponsors, physicians, students and, ultimately, the research subjects themselves. This pioneering project may become a future model for other public institutions in Brazil, principally in overcoming neglected diseases, which unfortunately continue to afflict this tropical country.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23333650     DOI: 10.1016/j.toxicon.2013.01.003

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Launching a CDMO in Brazil aiming to develop biopharmaceuticals for clinical trials.

Authors:  Rui Seabra Ferreira; Marcelo Marcos Morales; Pasqual Barretti; Benedito Barraviera
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2022-06-06

2.  Melittin induces in vitro death of Leishmania (Leishmania) infantum by triggering the cellular innate immune response.

Authors:  Andreia Vieira Pereira; Gustavo de Barros; Erika Gracielle Pinto; Andre Gustavo Tempone; Ricardo de Oliveira Orsi; Lucilene Delazari Dos Santos; Sueli Calvi; Rui Seabra Ferreira; Daniel Carvalho Pimenta; Benedito Barraviera
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2016-01-08

3.  BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells.

Authors:  Ana Rita Thomazela Machado; Alexandre Ferro Aissa; Diego Luis Ribeiro; Rui Seabra Ferreira; Suely Vilela Sampaio; Lusânia Maria Greggi Antunes
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-03-11

4.  Fibrin biopolymer as scaffold candidate to treat bone defects in rats.

Authors:  Claudia Vilalva Cassaro; Luis Antonio Justulin; Patrícia Rodrigues de Lima; Marjorie de Assis Golim; Natália Perussi Biscola; Mateus Vidigal de Castro; Alexandre Leite Rodrigues de Oliveira; Danuta Pulz Doiche; Elenize Jamas Pereira; Rui Seabra Ferreira; Benedito Barraviera
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-11-04

5.  A new fibrin sealant as a three-dimensional scaffold candidate for mesenchymal stem cells.

Authors:  Vinícius P O Gasparotto; Fernanda C Landim-Alvarenga; Alexandre L R Oliveira; Gustavo Ferreira Simões; João F Lima-Neto; Benedito Barraviera; Rui S Ferreira
Journal:  Stem Cell Res Ther       Date:  2014-06-10       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.